Matching articles for "fluoropyrimidine"
Fruquintinib (Fruzaqla) for Metastatic Colorectal Cancer (online only)
The Medical Letter on Drugs and Therapeutics • February 19, 2024; (Issue 1696)
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-,...
Fruquintinib (Fruzaqla – Takeda), an oral kinase
inhibitor, has been approved by the FDA for treatment
of adults with metastatic colorectal cancer (mCRC)
who received prior fluoropyrimidine-, oxaliplatin-, and
irinotecan-based chemotherapy, anti-VEGF therapy,
and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with
mCRC regardless of biomarker status. Fruquintinib
is the first drug to become available in the US for
treatment of mCRC that targets 3 VEGF receptor
kinases.
In Brief: A Second Indication for Tucatinib (Tukysa) (online only)
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type...
The oral kinase inhibitor tucatinib (Tukysa – Seagen)
has received accelerated approval from the FDA for
use in combination with trastuzumab (Herceptin)
for treatment of adults with RAS wild-type human
epidermal growth factor receptor 2 (HER2)-positive
unresectable or metastatic colorectal cancer
that has progressed following treatment with
fluoropyrimidine-, oxaliplatin-, and irinotecan-based
chemotherapy regimens. Tucatinib was approved in
2020 for use in combination with trastuzumab and
capecitabine (Xeloda, and generics) for treatment
of adults with advanced unresectable or metastatic
HER2-positive breast cancer, including those with
brain metastases, who received at least one prior
anti-HER2-based regimen for metastatic disease.